Royalty Pharma/RPRX

$28.19

0.11%
-
1D1W1MYTD1YMAX

About Royalty Pharma

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.

Ticker

RPRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Misc. Financial Services

CEO

Pablo Legorreta

Employees

89

Headquarters

New york, United States

Royalty Pharma Metrics

BasicAdvanced
$16.82B
Market cap
11.10
P/E ratio
$2.54
EPS
0.47
Beta
$0.80
Dividend rate
2.98%
Dividend yield
$16.82B
0.46595
$36.48
$25.92
2.71M
$0.80
7.896
94.006
94.006
31.58%
10.24%
18.67%
13.93%
11.103
7.145
1.927
2.578
32.734
2.84%
2.98%
5.24%
2,200.39%
3.52%
24.31%
38.67%

What the Analysts think about Royalty Pharma

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 6 analysts.
61.4% upside
High $60.00
Low $37.00
$28.19
Current price
$45.50
Average price target

Royalty Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
82.93% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$596M
11.13%
Net income
$494.3M
585.58%
Profit margin
82.93%
517.04%

Royalty Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 13.86%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$1.60
$0.84
$0.79
$1.15
-
Expected
$1.27
$0.81
$0.76
$1.01
$0.99
Surprise
25.65%
3.96%
4.5%
13.86%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Royalty Pharma stock?

Royalty Pharma (RPRX) has a market cap of $16.82B as of April 23, 2024.

What is the P/E ratio for Royalty Pharma stock?

The price to earnings (P/E) ratio for Royalty Pharma (RPRX) stock is 11.1 as of April 23, 2024.

Does Royalty Pharma stock pay dividends?

Yes, the Royalty Pharma (RPRX) stock pays dividends to shareholders. As of April 23, 2024, the dividend rate is $0.8 and the yield is 2.98%. Royalty Pharma has a payout ratio of 31.58% on a trailing twelve-month basis.

When is the next Royalty Pharma dividend payment date?

The next Royalty Pharma (RPRX) dividend payment is scheduled for June 14, 2024.

What is the beta indicator for Royalty Pharma?

Royalty Pharma (RPRX) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Royalty Pharma stock price target?

The target price for Royalty Pharma (RPRX) stock is $45.5, which is 63.55% above the current price of $27.82. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Royalty Pharma stock

Buy or sell Royalty Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing